Guardian Investment Management Has $589,000 Position in Pfizer Inc. (NYSE:PFE)

Guardian Investment Management lowered its position in Pfizer Inc. (NYSE:PFE) by 10.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 20,352 shares of the biopharmaceutical company’s stock after selling 2,250 shares during the period. Guardian Investment Management’s holdings in Pfizer were worth $589,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the business. Olistico Wealth LLC bought a new position in shares of Pfizer in the second quarter valued at approximately $25,000. MFA Wealth Advisors LLC purchased a new position in Pfizer during the 2nd quarter worth $29,000. Quarry LP bought a new stake in shares of Pfizer in the 2nd quarter worth $31,000. Creekmur Asset Management LLC purchased a new stake in shares of Pfizer in the fourth quarter valued at about $32,000. Finally, Trivant Custom Portfolio Group LLC boosted its holdings in Pfizer by 100.0% during the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 600 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

PFE has been the subject of several analyst reports. StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Wednesday. Barclays boosted their price objective on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and raised their target price for the company from $28.00 to $34.00 in a research report on Wednesday, August 7th. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Finally, Wells Fargo & Company raised their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Eight analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $34.54.

Pfizer Stock Performance

PFE traded down $0.18 on Friday, hitting $29.16. The company’s stock had a trading volume of 29,617,610 shares, compared to its average volume of 37,393,754. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $33.92. The firm has a market cap of $165.24 billion, a P/E ratio of -486.00, a price-to-earnings-growth ratio of 1.30 and a beta of 0.67. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. The company’s 50 day simple moving average is $29.04 and its 200-day simple moving average is $28.38.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.14. The company had revenue of $13.28 billion during the quarter, compared to analysts’ expectations of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The firm’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same period in the previous year, the business earned $0.67 earnings per share. Analysts forecast that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be given a $0.42 dividend. The ex-dividend date is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.76%. Pfizer’s dividend payout ratio (DPR) is currently -2,800.00%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.